Saama Technologies (Campbell, CA) has announced that it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium. The single goal, the company reports, is “to integrate data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50%.” Saama’s platform will allow researchers to dynamically visualize, analyze, and interrogate data across all available programs.
Suresh Katta, Founder and CEO of Saama Technologies, commented: “We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments - and hopefully a cure - for SARS-CoV-2.”
David Shulkin, M.D., the Ninth Secretary, US Department of Veterans Affairs, added: “We won’t find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented. In order to adequately address [it], we must share data from clinical studies across the research, healthcare, and pharma communities.”
Companies interested in joining the EndPandemic National Data Consortium to collaborate and accelerate solutions to the pandemic should contact Saama at endpandemic@saama.com or call 888.970.3550.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.